Sarepta taps ex-AbbVie exec Severino as new CEO

Good morning, healthcare professional.

Leadership changes, major acquisitions, and regulatory milestones are reshaping the pharmaceutical landscape today. Sarepta Therapeutics has named former AbbVie executive Michael Severino as its new CEO, while Argenx moves to acquire Forte Biosciences for $2.2 billion to expand its immune disease portfolio.

These developments signal strategic shifts at major biotechs as they navigate competitive pressures and seek growth opportunities. Meanwhile, the FDA's approval of Otsuka's ADHD treatment and promising Alzheimer's trial data underscore continued progress in addressing critical therapeutic needs.

In today's healthcare digest:

• Sarepta brings in AbbVie veteran to lead turnaround efforts
• Argenx makes $2.2 billion bet on immune disease pipeline
• FDA greenlights Otsuka's next major CNS product for ADHD
• Preliminary trial suggests path to safer Alzheimer's drugs

Sarepta Names Former AbbVie Executive as New CEO

The Recap: Sarepta Therapeutics has appointed Michael Severino, former AbbVie vice chairman and Tessera Therapeutics CEO, as its new chief executive. The leadership change comes as the Duchenne muscular dystrophy specialist seeks to reverse recent setbacks and capitalize on its specialized pipeline.

• Severino brings extensive pharma experience from his tenure at AbbVie, where he oversaw research and development operations.
• The appointment follows a period of challenges for Sarepta as it works to maximize its position in the rare disease market.
• Industry observers view the hire as significant given Severino's track record at major pharmaceutical companies and emerging biotechs.

Argenx Acquires Forte Biosciences for $2.2 Billion

The Recap: Argenx announced plans to acquire Forte Biosciences in a $2.2 billion deal, gaining access to what it describes as a differentiated immune disease drug targeting CD122. The transaction represents a major strategic expansion for the Belgian biotech company.

• The acquisition centers on Forte's CD122-targeted therapy, which Argenx believes offers distinct advantages in treating immune conditions.
• At $2.2 billion, the deal ranks among the larger biotech acquisitions this year and reflects confidence in the asset's potential.
• Argenx aims to leverage its commercial infrastructure to advance Forte's pipeline through development and regulatory approval.

FDA Approves Otsuka's ADHD Drug Simtriyo

The Recap: The FDA has approved Simtriyo, Otsuka's new ADHD treatment, setting up what the company calls its next major central nervous system launch. The approval provides another option for patients in the large and growing ADHD market.

• Simtriyo represents Otsuka's latest entry into the CNS space, where the company has established commercial presence with other products.
• ADHD affects millions of patients across age groups, creating substantial market opportunity for effective new treatments.
• The approval follows clinical trials demonstrating the drug's efficacy and safety profile in the target patient population.

Alzheimer's Trial Shows Promise for Safer Treatment Approach

The Recap: Preliminary trial results from Promis Neurosciences suggest a potential path toward Alzheimer's treatments with reduced risk of ARIA, the brain swelling and bleeding side effects that have limited current approved therapies. The early data addresses a critical safety concern with existing amyloid-targeting drugs.

• ARIA has emerged as a significant limitation for approved Alzheimer's drugs like Leqembi and Aduhelm, requiring careful patient monitoring.
• The trial data, while preliminary, indicates the investigational approach may offer improved safety without sacrificing efficacy.
• Alzheimer's disease affects millions globally, making any meaningful therapeutic advance highly significant for patients and healthcare systems.

The Shortlist

• Legend Biotech's CEO abruptly stepped down without a permanent replacement named, creating leadership uncertainty at the CAR-T therapy developer.

• AstraZeneca stayed on track for its $80 billion revenue goal as cancer medicines and rare disease sales offset a miss from Ultomiris.

• Outlook Therapeutics scored FDA approval on its fourth attempt for a reformulated version of Roche's Avastin to treat age-related macular degeneration.

• Sanofi halted development of amlitelimab in eczema, marking another setback for the troubled immune drug candidate.

• Ipsen faced another disappointment with its Albireo portfolio as Bylvay failed a phase 3 trial in a rare liver condition.